While Alx Oncology Holdings Inc has underperformed by -0.54%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALXO fell by -87.08%, with highs and lows ranging from $17.83 to $1.19, whereas the simple moving average fell by -68.25% in the last 200 days.
On December 19, 2024, Jefferies Downgraded Alx Oncology Holdings Inc (NASDAQ: ALXO) to Hold. A report published by Stifel on March 08, 2024, Downgraded its rating to ‘Hold’ for ALXO. Jefferies also Upgraded ALXO shares as ‘Buy’, setting a target price of $18 on the company’s shares in a report dated December 08, 2023. Jefferies December 22, 2021d the rating to Hold on December 22, 2021, and set its price target from $65 to $25. Stifel initiated its ‘Buy’ rating for ALXO, as published in its report on September 30, 2021. Credit Suisse’s report from May 05, 2021 suggests a price prediction of $98 for ALXO shares, giving the stock a ‘Outperform’ rating. Credit Suisse also rated the stock as ‘Outperform’.
Analysis of Alx Oncology Holdings Inc (ALXO)
Alx Oncology Holdings Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -98.94% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 4.82, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and ALXO has an average volume of 982.65K. On a monthly basis, the volatility of the stock is set at 12.46%, whereas on a weekly basis, it is put at 10.65%, with a gain of 10.78% over the past seven days. Furthermore, long-term investors anticipate a median target price of $8.40, showing growth from the present price of $1.85, which can serve as yet another indication of whether ALXO is worth investing in or should be passed over.
How Do You Analyze Alx Oncology Holdings Inc Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 41.39%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 55.65% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
ALXO shares are owned by institutional investors to the tune of 55.65% at present.
